News

Sobi announced that the European Commission (EC) has approved an indication extension for Aspaveli (pegcetacoplan) for treatment of adult patients with paroxysmal nocturnal…
Read More...

CytomX Therapeutics, Inc., a leader in the field of masked, conditionally activated biologic therapeutics, announced positive initial data from the ongoing CX-904 Phase 1a dose…
Read More...

iECURE, Inc., a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies for the treatment of liver disorders with…
Read More...

AstraZeneca announced the successful completion of an equity investment with Cellectis, a clinical-stage biotechnology company. The equity investment and a research collaboration…
Read More...

Novartis announced that it has entered into an agreement to acquire Mariana Oncology, a preclinical-stage biotechnology company based in Watertown, Massachusetts focused on developing…
Read More...

Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm), the company's…
Read More...

Janssen-Cilag International NV, a Johnson & Johnson company, announced it has submitted applications to the European Medicines Agency (EMA) seeking to expand the Marketing…
Read More...

Johnson & Johnson announced it is updating its brand and uniting both its two business segments under the Johnson & Johnson brand name in the UK. The announcement marks the…
Read More...

Bayer and the German-based life science company, Evotec, announced that they have updated the focus of their strategic collaboration to developing innovative precision treatments for…
Read More...

Enlaza Therapeutics, the first covalent biologic platform company, announced a $100 million Series A financing. The financing will be used to further develop Enlaza’s proprietary…
Read More...

Neurocrine Biosciences, Inc. announced the U.S. Food and Drug Administration has approved INGREZZA SPRINKLE (valbenazine) capsules, a new oral granules formulation of INGREZZA…
Read More...

Merck, a leading science and technology company, is investing more than € 300 million in a new research center at its global headquarters in Darmstadt, Germany. In the Advanced Research…
Read More...

Regeneron Pharmaceuticals, Inc. and Mammoth Biosciences, Inc., announced a collaboration to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple…
Read More...

Novartis announced that the U.S. Food and Drug Administration (FDA) approved Lutathera (USAN: lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for the treatment of…
Read More...

Incyte and Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small molecule therapeutics for systemic immune and neuro-immune disorders,…
Read More...

Positive results from the LUNA 3 phase 3 study demonstrated that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients…
Read More...

Ipsen and Skyhawk Therapeutics announced the signing of an exclusive worldwide collaboration to discover and develop novel small molecules that modulate RNA for rare neurological…
Read More...

Ochre Bio, a pioneer in chronic liver disease medicine development, announced a partnership with Boehringer Ingelheim focused on the discovery and development of novel, first-in-class…
Read More...

Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO (aztreonam-avibactam) for the treatment of adult patients with complicated…
Read More...

ImmunityBio, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for…
Read More...